U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H17FO3S
Molecular Weight 356.411
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SULINDAC, (R)-

SMILES

C[S@@+]([O-])C1=CC=C(\C=C2\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1

InChI

InChIKey=MLKXDPUZXIRXEP-LQVWSKNFSA-N
InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-/t25-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9221892

(R)-Sulindac is the (R)-enantiomer of nonsteroidal anti-inflammatory drug (NSAID) Sulindac, that is marketed in the U.S. by Merck as Clinoril. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver methionine sulfoxide reductases (Msr). The (Msr) family of enzymes includes two major classes, MsrA and MsrB, that specifically reduce the S- and R-epimers of Sulindac. Reduction of (R)-Sulindac to Sulindac Sulfide catalyzed by methionine sulfoxide reductase (Msr)-B. The oxidation of both epimers to sulindac sulfone is catalyzed primarily by the microsomal cytochrome P450 (P450) system. (S)-Sulindac increases the activity of the P450 system better than (R)-sulindac, but both epimers increase primarily the enzymes that oxidize (R)-sulindac. Both epimers can protect normal lung cells against oxidative damage and enhance the killing of lung cancer cells exposed to oxidative stress.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.02 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SULINDAC

Approved Use

CLINORIL is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. Osteoarthritis 2. Rheumatoid arthritis** 3. Ankylosing spondylitis 4. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 5. Acute gouty arthritis

Launch Date

1988
Primary
SULINDAC

Approved Use

CLINORIL is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. Osteoarthritis 2. Rheumatoid arthritis** 3. Ankylosing spondylitis 4. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 5. Acute gouty arthritis

Launch Date

1988
Primary
SULINDAC

Approved Use

CLINORIL is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. Osteoarthritis 2. Rheumatoid arthritis** 3. Ankylosing spondylitis 4. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 5. Acute gouty arthritis

Launch Date

1988
PubMed

PubMed

TitleDatePubMed
Studies on the metabolism and biological activity of the epimers of sulindac.
2011 Jun
Patents

Patents

Sample Use Guides

CLINORIL (Sulindac) should be administered orally twice a day with food. The maximum dosage is 400 mg per day. Dosages above 400 mg per day are not recommended. In osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, the recommended starting dosage is 150 mg twice a day. The dosage may be lowered or raised depending on the response.
Route of Administration: Oral
Fresh rat liver was minced and then homogenized using 5 strokes in a Potter-Elvehjem homogenizer with 3 volumes of 50 mM Tris-Cl, pH 7.4. The homogenate was centrifuged for 15 min at 10,000g, the pellet was discarded, and the supernatant was spun at 100,000g for 2 h to obtain crude microsomes. The microsomes were washed by resuspension in 3 volumes of the above buffer and centrifugation at 100,000g for 1 h. The microsomal pellet was finally resuspended in 3 volumes of the above buffer, aliquoted, and frozen at -80°C. The protein concentration was 25 mg/ml. In a total volume of 100 mkl, 20 nmol of each sulindac epimer were incubated with 20 to 80 mkg of microsomes and a NADPH-regenerating system (1.5 mM NADPH, 5 mM glucose 6-phosphate, 150 ng of glucose-6-phosphate dehydrogenase, and 5 mM MgCl2) in potassium phosphate buffer (pH 7.4, 100 mM) for 60 min at 37°C. The reaction was then stopped with 3 volumes of acetonitrile and centrifuged. The supernatant was fractionated by HPLC as described above.
Name Type Language
SULINDAC, (R)-
Common Name English
1H-INDENE-3-ACETIC ACID, 5-FLUORO-2-METHYL-1-((4-((R)-METHYLSULFINYL)PHENYL)METHYLENE)-, (1Z)-
Common Name English
(R)-SULINDAC
Common Name English
Code System Code Type Description
CAS
190967-68-1
Created by admin on Sat Dec 16 05:45:20 GMT 2023 , Edited by admin on Sat Dec 16 05:45:20 GMT 2023
PRIMARY
FDA UNII
1LZ36959EV
Created by admin on Sat Dec 16 05:45:20 GMT 2023 , Edited by admin on Sat Dec 16 05:45:20 GMT 2023
PRIMARY
PUBCHEM
16046677
Created by admin on Sat Dec 16 05:45:20 GMT 2023 , Edited by admin on Sat Dec 16 05:45:20 GMT 2023
PRIMARY